Nephro Trial Files Throwback Thursday: Revascularization in RAS, ACE+ARB in DM Nephropathy, and NS vs. Balanced Crystalloids in ICU
nephrotrialfiles.substack.com
Revascularization versus Medical Therapy for Renal-Artery Stenosis The ASTRAL Investigators. NEJM (November 2009) Bottom Line: This randomized, unblinded trial evaluated the effectiveness of percutaneous revascularization in addition to medical therapy compared to medical therapy alone in 806 patients with atherosclerotic renovascular disease. The primary outcome was renal function at 34 months, with secondary outcomes including blood pressure, time to renal and major cardiovascular events, and mortality. The results showed no significant difference in renal function between the two groups, but a higher risk of serious complications associated with revascularization. The study concluded that there was no worthwhile clinical benefit from revascularization in these patients.
Nephro Trial Files Throwback Thursday: Revascularization in RAS, ACE+ARB in DM Nephropathy, and NS vs. Balanced Crystalloids in ICU
Nephro Trial Files Throwback Thursday…
Nephro Trial Files Throwback Thursday: Revascularization in RAS, ACE+ARB in DM Nephropathy, and NS vs. Balanced Crystalloids in ICU
Revascularization versus Medical Therapy for Renal-Artery Stenosis The ASTRAL Investigators. NEJM (November 2009) Bottom Line: This randomized, unblinded trial evaluated the effectiveness of percutaneous revascularization in addition to medical therapy compared to medical therapy alone in 806 patients with atherosclerotic renovascular disease. The primary outcome was renal function at 34 months, with secondary outcomes including blood pressure, time to renal and major cardiovascular events, and mortality. The results showed no significant difference in renal function between the two groups, but a higher risk of serious complications associated with revascularization. The study concluded that there was no worthwhile clinical benefit from revascularization in these patients.